HomeCompareHHDS vs ABBV

HHDS vs ABBV: Dividend Comparison 2026

HHDS yields 1947.42% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 HHDS wins by $7757039411.80M in total portfolio value
10 years
HHDS
HHDS
● Live price
1947.42%
Share price
$0.10
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$7757039411.90M
Annual income
$7,045,364,447,504,868.00
Full HHDS calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — HHDS vs ABBV

📍 HHDS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodHHDSABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, HHDS + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
HHDS pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

HHDS
Annual income on $10K today (after 15% tax)
$165,530.67/yr
After 10yr DRIP, annual income (after tax)
$5,988,559,780,379,138.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, HHDS beats the other by $5,988,559,780,358,082.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of HHDS + ABBV for your $10,000?

HHDS: 50%ABBV: 50%
100% ABBV50/50100% HHDS
Portfolio after 10yr
$3878519706.00M
Annual income
$3,522,682,223,764,820.00/yr
Blended yield
90.83%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

HHDS
No analyst data
Altman Z
-4.8
Piotroski
5/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

HHDS buys
0
ABBV buys
0
No recent congressional trades found for HHDS or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricHHDSABBV
Forward yield1947.42%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$7757039411.90M$102.3K
Annual income after 10y$7,045,364,447,504,868.00$24,771.77
Total dividends collected$7706421709.00M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: HHDS vs ABBV ($10,000, DRIP)

YearHHDS PortfolioHHDS Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$205,442$194,741.97$11,550$430.00+$193.9KHHDS
2$3,958,904$3,739,081.56$13,472$627.96+$3.95MHHDS
3$71,575,083$67,339,055.17$15,906$926.08+$71.56MHHDS
4$1,214,396,210$1,137,810,871.42$19,071$1,382.55+$1214.38MHHDS
5$19,341,410,844$18,042,006,899.05$23,302$2,095.81+$19341.39MHHDS
6$289,247,571,014$268,552,261,410.64$29,150$3,237.93+$289247.54MHHDS
7$4,062,910,085,069$3,753,415,184,084.88$37,536$5,121.41+$4062910.05MHHDS
8$53,620,462,900,612$49,273,149,109,587.61$50,079$8,338.38+$53620462.85MHHDS
9$665,116,789,152,691$607,742,893,849,036.50$69,753$14,065.80+$665116789.08MHHDS
10$7,757,039,411,898,247$7,045,364,447,504,868.00$102,337$24,771.77+$7757039411.80MHHDS

HHDS vs ABBV: Complete Analysis 2026

HHDSStock

Our portfolio consists of office, industrial, retail and apartment assets, an unoccupied correctional facility and unimproved land. This portfolio largely represented the non-core assets of InvenTrust Properties Corp., our former parent, which spun off Highlands REIT in 2016. The spin-off allowed InvenTrust's management to focus on its core portfolio while providing Highlands with a dedicated management team to focus on maximizing the value of our portfolio.

Full HHDS Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this HHDS vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

HHDS vs SCHDHHDS vs JEPIHHDS vs OHHDS vs KOHHDS vs MAINHHDS vs JNJHHDS vs MRKHHDS vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.